Glaukos says Phase 4 trial shows iDose TR plus cataract surgery cuts mean diurnal IOP more than surgery alone

Bitget2026/10/09 11:00

Glaukos reported positive topline results from a Phase 4 trial of iDose TR used during cataract surgery. Results have been presented as topline data, not flagged for a future medical meeting in the announcement. Patients receiving iDose TR with surgery showed better eye-pressure control than cataract surgery alone. Safety profile through three months looked favorable, with no treatment-related serious corneal events reported. Data support broader use of iDose TR in combined procedures, potentially expanding adoption beyond standalone glaucoma intervention. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009307901) on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37